Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 02, 2022

ESC 2022: Meta-Analysis Reveals Benefits of Long-Term P2Y12 Inhibitor Over Aspirin in Coronary Artery Disease

Findings suggest P2Y12 inhibitor monotherapy should be selected over aspirin monotherapy in secondary prevention

PracticeUpdate Editorial Team


Further Reading